AstraZeneca PLC AZN
189.39 USD +2.96 (+1.59%)
At closeNov 9, 2026, 5:41 PM EST
189.39 0.00 0.00%
After hours · Nov 9, 5:41 PM ET
187.21 Day range 190.17
153.41 52-week range 212.71
- YTD
- +3.01%
- 1 year
- +11.96%
News
defenseworld.net AstraZeneca Plc (NYSE:AZN) Stock Has Average Price Target of $206.67 According to Brokerages AstraZeneca Plc (NYSE: AZN - Get Free Report) has received a consensus rating of "Moderate Buy" from the nineteen ratings firms that are currently covering the firm, MarketBeat reports. Three…
wsj.com AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.
benzinga.com Drugmaker CEOs Say AI Alone Can't Cure Diseases, Challenge Silicon Valley's Bold Predictions: 'To Say AI Is Going to Cure Cancer...' Drugmaker executives doubt AI will cure disease soon, saying biology is too complicated.
benzinga.com AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar Timing AstraZeneca posts strong Q3; RBC raises target, citing reduced AVANZAR uncertainty and promising pipeline catalysts.
benzinga.com Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter Regeneron, AstraZeneca and Exelixis show overbought RSI readings after strong gains, warning momentum-focused investors of potential pullbacks.
defenseworld.net 27,056 AstraZeneca Plc $AZN Shares Acquired by International Assets Investment Management LLC International Assets Investment Management LLC boosted its stake in AstraZeneca Plc (NYSE: AZN) by 1,564.8% in the undefined quarter, according to its most recent filing with the SEC. The fund owned…
defenseworld.net 1,929,102 Shares of AstraZeneca Plc $AZN Acquired by Bank Julius Baer & Co. Ltd Zurich Bank Julius Baer and Co. Ltd Zurich bought a new stake in AstraZeneca Plc (NYSE: AZN) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission.…
benzinga.com AstraZeneca Q3 2026 Earnings Call Transcript AstraZeneca (NASDAQ:AZN) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com AstraZeneca Stock Rallies on Q3 Earnings Beat, Double-Digit Oncology Growth AstraZeneca beats Q3 2026 targets as oncology offsets Farxiga losses, backed by a $2 billion pipeline restructuring push.
benzinga.com AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday U.S. stocks fell Friday, but AutoNation jumped 8% after beating Q3 estimates; OneSpan, Grid Dynamics and others posted double-digit gains.
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Trade Mixed as AMZN, INTC Slide After Q3 Earnings—DELL, LLY, AZN in Focus (UPDATED) U.S. stock were mixed on Friday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures moved in different direction.
benzinga.com AstraZeneca Shares Rise After Q3 Earnings Beat, Reaffirmed 2026 Outlook AstraZeneca Plc (NASDAQ:AZN) shares are trading higher Friday after the drugmaker reported third-quarter results that topped analyst estimates and reaffirmed its full-year guidance.What To Know:…
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will S&P 500 open higher? Polymarket odds plunge to 14% as Wall Street reacts to Alphabet's 10% drop, rising oil, and a broad tech selloff.
benzinga.com ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test ExxonMobil headlines Friday’s reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. AbbVie, Chevron, AstraZeneca, BP, Sanofi, General Dynamics,…
benzinga.com Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1 Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1First EU…
benzinga.com Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer Amgen's Imdelltra with Imfinzi cut small-cell lung cancer death risk by 58% in Phase 3, extending median survival to 21.1 months. Read more.
benzinga.com AstraZeneca Announced Saturday,Perioperative IMFINZI Plus Neoadjuvant Enfortumab Vedotin Cuts Recurrence Risk 49%, Death Risk 42% Versus Standard Of Care In Muscle-Invasive Bladder Cancer Patients Ineligible For Or Refusing Cisplatin, VOLGA Phase III More than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgeryData demonstrated statistically significant and…
benzinga.com AstraZeneca Announced Saturday, IMFINZI Plus Tarlatamab-dlle Cuts Death Risk 58% Versus IMFINZI Alone In First-Line Extensive-Stage Small Cell Lung Cancer, Median OS 21.1 Versus 12.7 Months, In DeLLphi-305 Phase III Novel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trialResults reinforce IMFINZI as the…
benzinga.com FDA Conditionally Approves AstraZeneca's Rare Kidney Disease Drug FDA grants accelerated approval to AstraZeneca's Ultomiris for adult IgAN to lower proteinuria, pending data on long-term kidney benefit.
benzinga.com AstraZeneca Launches ZEGFROVY In The U.S., Expanding Targeted Treatment Options For EGFR Exon 20 Insertion-Mutated Lung Cancer Only approved oral, single agent, targeted therapy for these patients following platinum-based chemotherapyLaunch expands AstraZeneca’s commitment to addressing substantial unmet need across the…
benzinga.com Reported Earlier, AstraZeneca’s Alexion Wins US Accelerated Approval For Ultomiris As First C5 Inhibitor To Reduce Proteinuria In IgA Nephropathy Adults; Phase III I CAN Shows 43.4% Reduction Versus Placebo At 34 Weeks Based on I CAN Phase III trial results from prespecified interim analysis in which Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks Late-breaking results from I CAN Phase…
benzinga.com AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.
benzinga.com 'A Surprisingly Large Amount Of Your Investment Is Divided Across Just 7 Companies' — Former Investment Banker Says She's Changing How She Invests The S&P 500 has long been a favorite among investors looking to build wealth, with historical annual returns averaging around 10%. But former investment banker Nischa Shah says she’s changing how she…- benzinga.com Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and…
benzinga.com AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs.…
benzinga.com Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research Oracle and AstraZeneca partner to advance AI-driven clinical trials, speed up recruitment, and connect research to patient care.
benzinga.com Oracle Announces Non-Binding Agreement With AstraZeneca To Explore AI And Real-World Data For Clinical Trial Patient Identification, Evidence Generation And Care Insights Collaboration to connect AstraZeneca's scientific and therapeutic expertise with Oracle's real-world data, cloud, AI, and clinical capabilities to accelerate clinical research and bring…
benzinga.com Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.- benzinga.com AstraZeneca To Present 100+ Cancer Research Abstracts, Including Five Phase III Trials, At ESMO 2026 CLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of CLDN18.2-positive gastric cancer patientsSAFFRON results will highlight clinical…
benzinga.com AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal AstraZeneca pairs with Insitro on a $1.5B AI collaboration to advance drug targets for MASH and heart conditions.
benzinga.com AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal AstraZeneca releases Phase 3 HICKORY trial data for efzimfotase alfa in hypophosphatasia (HPP), showing key secondary improvements.
benzinga.com Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAH Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographiesThis latest approval marks Guardant’s 31st CDx approval- benzinga.com SOPHiA GENETICS, Myriad Genetics Collaborate To Advance New Prostate Cancer-specific Genomic Instability Score Technology SOPHiA GENETICS (NASDAQ:SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support…
- benzinga.com AstraZeneca Announces The Opening Of Its Newest Global Strategic Research And Development Center, In Kendall Square, Cambridge, Massachusetts; Co. invests $1B To Grow Massachusetts Workforce By Over 50% $1 billion investment will grow AstraZeneca’s workforce in Massachusetts by over 50% and deliver next-generation medicinesAstraZeneca today announced the opening of its newest global strategic…
benzinga.com AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership AstraZeneca & Daiichi Sankyo team up with Summit Therapeutics to test Datroway + ivonescimab combo in triple-negative breast cancer.- benzinga.com Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com AstraZeneca Invests in Summit Therapeutics after Year of Speculation AstraZeneca buys $2 billion in Summit Therapeutics equity to test ivonescimab with ADCs, providing capital.
benzinga.com Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab AstraZeneca invests $2 billion in Summit Therapeutics to combine cancer drugs ivonescimab and Sone-Ve.- benzinga.com Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —Application…
- benzinga.com AstraZeneca Has Entered Into An Agreement To Invest $2B In Newly Issued Equity In Summit Therapeutics To Accelerate The Development Of Ivonescimab, A First-In-Class Bispecific Antibody Targeting PD-1 And VEGF, In Combination With Antibody Drug Conjugates Across Tumour Types; Summit And AstraZeneca Have Also Entered Into A Clinical Collaboration Agreement To Evaluate Sonesitatug Vedotin In Combination With Ivonescimab https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-equity-investment-summit.html
- benzinga.com AstraZeneca's IMFINZI-EV Combo For Muscle-Invasive Bladder Cancer Granted FDA Priority Review; PDUFA Decision Expected Q4 2026 Based on VOLGA Phase III trial results which demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survivalAstraZeneca’s supplemental…
- benzinga.com The FDA Accepts And Grants Priority Review to AstraZeneca’s Supplemental Biologics License Application For Imfinzi (Durvalumab) Combined With Enfortumab Vedotin For Muscle-invasive Bladder Cancer Who Are Ineligible For Or Have Declined Cisplatin-based Chemotherapy https://www.astrazeneca.com/media-centre/press-releases/2026/perioperative-imfinzi-plus-neoadjuvant-enfortumab-vedotin-granted-priority-review-in-the-us-for-patients-with-muscle-invasive-bladder-cance…
benzinga.com Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer The FDA fully approves Eli Lilly's Inluriyo and Verzenio combination for advanced breast cancer, doubling progression-free survival.
benzinga.com This $3 Biotech Could Be Worth $11.45, Analyst Says William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Transcript: AstraZeneca Q2 2026 Earnings Conference Call On Monday, AstraZeneca (NASDAQ:AZN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
benzinga.com This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
benzinga.com AstraZeneca, Leidos, Expeditors International And More On CNBC’s ‘Final Trades’ CNBC traders picked AstraZeneca, Leidos, 10-year Treasuries and Expeditors; strong earnings lifted Leidos and Expeditors shares.
benzinga.com Cellectis Pivots to Gene Editing in Major Overhaul Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipeline updates on .HEAL-101 & .HEAL-201.